Inhibition of respiratory syncytial virus by RhoA-derived peptides: Implications for the development of improved antiviral agents targeting heparin-binding viruses

Philip J. Budge, Barney S. Graham

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

The respiratory syncytial virus (RSV) fusion glycoprotein (F) can interact with the small intracellular GTPase RhoA, and peptides derived from RhoA inhibit RSV replication. These observations initially suggested that RhoA-derived peptides might inhibit RSV replication by disrupting an in vivo interaction between RSV F and RhoA. However, recent data indicate that the antiviral activity of RhoA-derived peptides is not due to competitive inhibition of an hypothesized F-RhoA interaction, but is rather a function of the peptides' intrinsic biophysical properties. We summarize here what is known about the mechanism of RSV inhibition by these peptides and give our opinion regarding the potential implications of this work with regards to RSV biology, and to the development of antiviral agents targeting RSV and other enveloped viruses.

Original languageEnglish
Pages (from-to)299-302
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume54
Issue number2
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Keywords

  • Antiviral agents
  • Dextran sulphate
  • Fusion inhibition
  • HIV
  • Heparan sulphate
  • Heparin
  • Human immunodeficiency virus
  • Polyanions
  • Post-attachment neutralization
  • RSV
  • Sulphated polysaccharides

Fingerprint Dive into the research topics of 'Inhibition of respiratory syncytial virus by RhoA-derived peptides: Implications for the development of improved antiviral agents targeting heparin-binding viruses'. Together they form a unique fingerprint.

  • Cite this